ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 Feb 27, 2026 07:30AM
ImmunityBio completes enrollment in bladder cancer trial ahead of schedule Feb 26, 2026 07:31AM
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ Feb 26, 2026 07:30AM
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit Feb 23, 2026 04:15PM
ImmunityBio starts phase 2 trial for chemotherapy-free lymphoma treatment Feb 2, 2026 07:00AM
View Older Stories

Feb 2, 2026 07:00AM ImmunityBio begins phase 2 trial of chemotherapy-free lymphoma treatment
Feb 2, 2026 07:00AM ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
Jan 23, 2026 07:00AM ImmunityBio reports survival data from glioblastoma trial
Jan 23, 2026 07:00AM ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Jan 20, 2026 04:00AM ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
Jan 16, 2026 07:00AM ImmunityBio reports 15-month response in lymphoma cell therapy trial
Jan 16, 2026 07:00AM ImmunityBio reports progress in bladder cancer trial enrollment
Jan 16, 2026 07:00AM ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
Jan 16, 2026 07:00AM ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
Jan 15, 2026 08:32AM ImmunityBio reports $113 million revenue, 700% annual increase
Jan 15, 2026 08:30AM ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
Jan 14, 2026 08:30AM ImmunityBio gets Saudi approval for bladder cancer treatment ANKTIVA
Jan 14, 2026 08:30AM Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Jan 14, 2026 08:30AM Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
Jan 13, 2026 08:30AM ImmunityBio reports positive lung cancer trial results for ANKTIVA
Jan 13, 2026 08:30AM ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Jan 12, 2026 08:30AM NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
Dec 29, 2025 09:00AM ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
Dec 16, 2025 09:01AM ImmunityBio's ANKTIVA shows 96% survival in bladder cancer study
Dec 16, 2025 09:00AM ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment
Dec 12, 2025 06:10AM ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in
Nov 13, 2025 09:00AM New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Nov 4, 2025 10:12PM Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Sep 8, 2025 08:30AM ImmunityBio reports ANKTIVA therapy reverses lymphopenia in lung cancer
Sep 8, 2025 08:30AM ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
Aug 26, 2025 08:31AM ImmunityBio reports early trial results in brain cancer treatment
Aug 26, 2025 08:30AM Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optu
Aug 19, 2025 08:30AM ImmunityBio launches phase 2 trial of ANKTIVA for long COVID treatment
Aug 19, 2025 08:30AM ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
Aug 13, 2025 08:31AM ImmunityBio reports complete responses in lymphoma trial with CAR-NK therapy
Aug 13, 2025 08:30AM ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Aug 11, 2025 08:30AM ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
Aug 5, 2025 07:00AM ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Jul 25, 2025 06:06AM ImmunityBio raises $80 million from institutional investors
Jul 25, 2025 06:03AM ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
Jul 25, 2025 06:00AM ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
Jul 7, 2025 09:43PM UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Jun 3, 2025 08:45AM ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
Jun 2, 2025 09:02AM ImmunityBio (IBRX) receives FDA Expanded Access for Cancer BioShield platform
Jun 2, 2025 09:00AM ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
May 27, 2025 08:00AM ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
May 12, 2025 06:30AM ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
May 5, 2025 07:51AM ImmunityBio (IBRX) receives Refusal to File letter from FDA for sBLA for use of ANKTIVA plus Bacillus Calmette-Guerin
May 5, 2025 06:30AM ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inc
Apr 28, 2025 08:30AM Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i
Apr 21, 2025 04:21PM ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Apr 15, 2025 08:01AM ImmunityBio (IBRX) Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Apr 15, 2025 08:00AM ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Apr 8, 2025 07:32AM ImmunityBio (IBRX) Announces Execution of $75 Million Equity Financing with an Institutional Investor
View Older Stories